TianJin Medical University Eye Hospital is involved in conducting clinical trials and providing information related to eye health and medical studies, self-described as a better way to connect patients with study teams.

TianJin Medical University Eye Hospital

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Friedrich Bayer

Johann Friedrich Weskott

Bayer Aktiengesellschaft

SCHWIND eye-tech-solutions is a leading provider of advanced femtosecond laser technology, particularly known for its SCHWIND ATOS® system. This technology is used in refractive surgery to create LASIK flaps and lenticules for laser-assisted lenticular extraction, such as the SmartSight procedure. The company's products are praised for their precision, safety, and patient comfort, with features like low-energy delivery, eye tracking, and cyclotorsion compensation.

SCHWIND eye-tech-solutions

Genentech, Inc. is an American biotechnology corporation dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. It is a proud member of the Roche Group, making medicines to treat patients with serious medical conditions.

Metric
Company Name	TianJin Medical University Eye Hospital	Bayer Aktiengesellschaft	SCHWIND eye-tech-solutions	Genentech, Inc.
Symbol		BAYN
MSH ID	COM:PATIENTWING:APP	COM:BAYER	COM:EYE-TECH-SOLUTIONS	COM:GENE
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical & Healthcare	Drug Manufacturers - General	Medical Devices	Biotechnology
Country	CN	DE	DE	US
Stage
Employee Count		98.19K	124	20.35K
Website	app.patientwing.com/organization	bayer.com	eye-tech-solutions.com	gene.com
LinkedIn		bayer	schwind-eye-tech-solutions	genentech
Founders

Metric
Market Cap		27.44B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		50.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit		29.46B
EBITDA		13.04B
Operating Income		8.88B
Net Income		-3.11B
EPS		-3.16
Diluted EPS		-3.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.59
Operating Profit Margin		0.08
EBITDA Margin		0.26
Net Profit Margin		-0.03
Return on Equity		-0.04
Return on Assets		-0.01
Return on Capital Employed		0.04

PATI

COM:PATIENTWING:APP

TianJin Medical University Eye Hospital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-7.66
P/B Ratio		0.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.63
EV Multiple		-0.89

Metric
Days Sales Outstanding
Days Payables Outstanding		118.44
Days Inventory Outstanding		257.77
Operating Cycle		389.93
Cash Conversion Cycle		270.05
Asset Turnover		0.39

Metric
Operating Cash Flow		4.29B
Free Cash Flow		1.38B
Cash Flow to Debt		0.16
Operating Cash Flow/Sales		0.16
Free Cash Flow Yield		-0.02

Metric
Cash & Equivalents		6.24B
Accounts Receivable		727.74M
Inventory		14.73B
Goodwill		34.12B
Debt to Capitalization		0.57
Debt to Assets		0.41
Current Ratio		1.13
Quick Ratio		0.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.12
SG&A to Revenue		0.05